Etiology and pathogenesis of Parkinson's disease

Annual Review of Neuroscience

Volumn 22, Issue , 1999, Pages 123-144

  Olanow, C W ^a   Tatton, W G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Dopamine neurons; Neuroprotection; Oxidant stress; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; ANTIOXIDANT; ANTIPARKINSON AGENT; CYTOKINE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG METABOLITE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTATHIONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTROPHIC FACTOR; REMACEMIDE; RILUZOLE; SELEGILINE; UBIQUINONE;

APOPTOSIS; BRAIN PROTECTION; DEGENERATIVE DISEASE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; GENE MUTATION; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

APOPTOSIS; HUMANS; IMMUNE SYSTEM; MITOCHONDRIA; NERVE GROWTH FACTORS; NEUROGLIA; NEUROTOXINS; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 0032936755     PISSN: 0147006X     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.neuro.22.1.123     Document Type: Review

References (128)

1. Agid Y. 1995. Aging, disease and nerve cell death. Bull. Acad. Natl. Med. 179:1193-203
2. Aisen PS, Marin D, Altstiel L, Goodwin C, Bauch B, et al. 1996. A pilot study of prednisone in Alzheimer's disease. Dementia 7:201-6
3. Alam ZI, Daniel SE, Lees AJ, Marsden CD, Jenner P, Halliwell B. 1997a. A generalized increase in protein carbonyls in the brain in Parkinson's but not Incidental Lewy Body disease. J. Neurochem. 69:1326-29
4. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, et al. 1997b. Oxidative DNA damage in the parkinsonian brain; a selective increase in 8-hydroxyguanine in substantia nigra? J. Neurochem. 69:1196-203
5. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, et al. 1997. Apoptosis and autophagie in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12:25-31
6. Asada H, Ip NY, Pan L, Razack N, Parfitt MM, Plunkett RJ. 1995. Time course of ciliary neurotrophic factor mRNA expression is coincident with the presence of protoplasmic astrocytes in traumatized rat striatum. J. Neurosci. Res. 40:22-30
7. Bandmann O, Vaughan J, Holmans P, Marsden CD, Wood NW. 1997. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 350:1136-39
8. Beal MF. 1992. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31:119-30
9. Beckman JS, Beckman TW, Chen J, et al. 1990. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 87:1620-24
10. Bolanos JP, Heales SJR, Peuchen S, et al. 1996. Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. Free Radic. Biol. Med. 21:995-1001
11. Bredesen DE. 1995 Neural apoptosis. Ann. Neurol. 38:839-51
12. Castagnoli K, Palmer S, Anderson A, et al. 1997. The neural nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem. Res. Toxicol. 10:364-68
13. Chadi G, Cao Y, Pettersson RF, Fuxe K. 1994. Temporal and spatial increase of astroglial basic fibroblast growth factor synthesis after 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine neurons. Neuroscience 61:891-910
14. Connor JR, Snyder BS, Arosio P, et al. 1995. Quantitative analysis of isoferritins in select regions of aged, Parkinsonian, and Alzheimer diseased brains. J. Neurochem. 65:717-24
15. Crawford GD, Le WD, Smith RG, Xie WJ, Stefani E, Appel SH. 1992. A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J. Neurosci. 12:3392-98
16. Davey GP, Clark JB. 1996. Threshold effects and control of oxidative phosphorylation in non-synaptic rat brain mitochondria. J. Neurochem. 66:1617-24
17. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. 1991. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA 88:6368-71
18. DeLong MR. 1990. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:281-89
19. Desagher S, Glowinski J, Premont J. 1996. Astrocytes protect neurons from hydrogen peroxide toxicity. J. Neurosci. 16:2553-62
20. Dexter DT, Carter CJ, Wells FR, et al. 1989b. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:381-89
21. Dexter DT, Holley AE, Flitter WD, et al. 1994b. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9:92-97
22. Dexter DT, Sian J, Rose S, et al. 1994a. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35:38-44
23. Dexter DT, Wells FR, Lees AJ, et al. 1989a. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1830-36
24. DiMauro S. 1993. Mitochondrial involvement in Parkinson's disease: the controversy continues. Neurology 43:2170-72
25. Faucheux B, Nillesse N, Damier P, et al. 1995. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson's disease. Proc. Natl. Acad. Sci. USA 92:9603-7
26. Gash DM, Zhang ZM, Cass WA, Ovadia A, Simmerman L, et al. 1995. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J. Comp. Neurol. 363:345-58
27. Gash DM, Zhang Z, Gerhardt G. 1998. Neuroprotective and neurorestorative properties of GDNF. Ann. Neurol. In press
28. Gasser T, Wszolek ZK, Trofatter J, et al. 1994. Genetic studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann. Neurol. 36:387-96
29. George JM, Jin H, Woods WS, Clayton DP. 1995. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15:361-72
30. Golbe L. 1990. The genetics of Parkinson's disease: a reconsideration. Neurology 40:7-14
31. Good P, Olanow CW, Perl DP. 1992. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study. Brain Res. 593:343-46
32. Good PF, Hsu A, Werner P, Perl DP, Olanow CW. 1998. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol.
33. Good PF, Olanow CW, Hsu A, Gordon J. 1997. SOD-1 G86R transgenic mice have decreased striatal dopamine and a greater sensitivity to MPTP than control mice. Soc. Neurosci. 23:1877 (Abstr.)
34. Greenmayre TE, Eller RV, Zhang Z, et al. 1994. Antiparkinsonian effects of ramacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. 35:655-61
35. Grilli M, Pizzi M, Mano M, Spano P. 1996. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 22:1383-85
36. Hagg T, Quon D, Higaki J, Varon S. 1992. Ciliary neurotrophic factor prevents neuronal degeneration and promotes low affinity NGF receptor expression in the adult rat CNS. Neuron 8:145-48
37. Hagg T, Varon S. 1993. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc. Natl. Acad. Sci. USA 90:6315-19
38. Halliwell B, Gutteridge J. 1985. Oxygen radicals and the nervous system. Trends Neurosci. 8:22-29
39. Ham J, Babij C, Whitfield J, Pfarr CM, Lallemand D, et al. 1995. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 14:927-39
40. Hantrave P, Brouillet E, Ferrante R, et al. 1996. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. 2:1017-21
41. Hirsch EC, Hunot S, Damier P, Faucheux B. 1998. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol. In press
42. Hunot S, Bernard V, Faucheux B, Boissiere F, Leguern E, et al. 1996. Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: a post mortem in situ hybridization study with special reference to Parkinson's disease. J. Neural Transm. 103:1043-52
43. Hunot S, Brugg B, Ricard D, et al. 1997. Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. USA 94:7531-36
44. Hyman C, Hofer M, Barde Y-A, Juhasz M, Yancopoulos GD, et al. 1991. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350:230-32
45. Ikebe S, Tanaka M, Ozawa T. 1995. Point mutations of mitochondrial genome in Parkinson's disease. Mol. Brain Res. 28:281-95
46. Ischiropoulos H, Zhu L, Chen J, et al. 1992. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 298:431-37
47. Ishitani R, Kimura M, Sunaga K, Katsube N, Tanaka M, Chuang DM. 1996. An antisense oligonucleotide to glyderaldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebro-cortical neurons in culture. J. Pharm. Exp. Ther. 278:447-54
48. Jenner P, Olanow CW. 1996. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47:161-70
49. Jenner P, Olanow CW. 1998. Understanding cell death in Parkinson's disease. Ann. Neurol. In press
50. Johnson SW, Seutin V, North A. 1992. Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump. Science 258:665-67
51. Kholodilov NG, Neystat M, Burke RE. 1997. mRNAs overexpressed during induced apoptosis in substantia nigra identified by RNA differential display. Soc. Neurosci. 23:631 (Abstr.)
52. Kroemer G, Petit P, Xamzami N, Vayssierre JL, Mignotte B. 1995. The biochemistry of programmed cell death. FASEB 9:1277-87
53. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, et al. 1998. AIa30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18:106-8
54. Langston JW, Ballard PA, Tetrud JW, Irwin I. 1983. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 219:979-80
55. Lapchak PA, Miller PJ, Collins F, Jiao S. 1997. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience 78:61-72
56. Lestienne P, Nelson J, Riederer P, Jellinger K, Reichmann H. 1990. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J. Neurochem. 55:1810-12
57. Levi-Montalcini R, Hamburger V. 1953. A diffusible agent of mouse sarcoma producing hyperplasia of sympathetic ganglia and hyperneurotization of the chick embryo. J. Exp. Zool. 123:233-88
58. Lin WW, Doherty DH, Lile JD, Bektesh S, Collins F. 1993. GDNF: a glial cell-line derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-32
59. Liu XS, Kim CN, Yang J, Jemmerson R, Wang XD. 1996. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86:147-57
60. Maroteaux L, Campanelli JT, Scheller RH. 1988. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8:2804-15
61. McGeer PL, Itagaki S, McGeer EG. 1988. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 76:550-57
62. McGeer PL, Schulzer M, McGeer EG. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47:425-32
63. Mizuno Y, Matuda S, Yoshino H, et al. 1994. An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 35:204-10
64. Mochizuki H, Goto K, Mori H, Mizuno Y. 1996. Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 131:120-23
65. Mogi M, Harada M, Kondo T, Mizuno Y, Narabayashi H, et al. 1996. BCL-2 protein is increased in the brain of parkinson patients. Neurosci. Lett. 215:137-39
66. Mytilineou C, Han S-K, Cohen G. 1993. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J. Neurochem. 61:1470-78
67. Mytilineou C, Leonardi EK, Radcliffe P, Heinonen EH, Han SK, et al. 1998. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J. Pharm. Exp. Ther. 284:700-6
68. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW. 1997a. L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J. Neurochem. 68:33-39
69. Mytilineou C, Radcliffe PM, Olanow CW. 1997b. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J. Neurochem. 68:434-36
70. Newmeyer DD, Farschon DM, Reed JC. 1994. Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 79:353-64
71. Nicklas WJ, Vyas I, Heikkila RE. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:2503-8
72. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash G. 1994. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660:8-18
73. Ogawa N, Asanuma M, Kondo Y, et al. 1994. Differential effects of chronic L-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydro-xydopamine. Neurosci. Lett. 171:55-58
74. Okuda Y, Sakoda S, Fujimara H, Yamagihara T. 1997. Pentoxyfylline delays the onset of experimental allergic encephalomyelitis in mice by modulating cytokine production in peripheral blood mononuclear cells. Immunopharmacology 35:141-48
75. Olanow CW. 1990. Oxidation reactions in Parkinson's disease. Neurology 40:32-37
76. Olanow CW. 1993. A radical hypothesis for neurodegeneration. Trends Neurosci. 16:439-44
77. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, et al. 1995. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol. 38:771-77
78. Olanow CW, Jenner P, Tatton N, Tatton WG. 1998. Neurodegeneration in Parkinson's disease. In Parkinson's Disease and Movement Disorders, ed. J Jankovic, E Tolosa, pp. 67-103. Baltimore, MD: Williams & Wilkins. 3rd ed.
79. Olanow CW, Youdim MHB. 1996. Iron and neurodegeneration: prospects for neuroprotection. In Neurodegeneration and Neuroprotection in Parkinson's Disease, ed. CW Olanow, P Jenner, MHB Youdim, pp. 55-67. London: Academic
80. Parkinson's Study Group. 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:176-83
81. Piallat B, Bennazouz A, Bressand L, et al. 1996. Subthalamic nucleus lesion in rat prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection. Eur. J. Neurosci. 8:1408-14
82. Pileblad E, Magnusson T, Fornstedt B. 1989. Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum. J. Neurochem. 52:978-80
83. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, et al. 1996. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274:1197-99
84. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276:2045-47
85. Polymeropoulos MH. 1998. Autosomal dominant Parkinson's disease and alpha synuclein. Ann. Neurol. In press
86. Przedborski S, Jackson Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. 1996. Role of neuronal oxide in l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. USA 93:4565-66
87. Rodriguez MC, Obeso JA, Olanow CW. 1998. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a possible target for neuroprotection. Ann. Neurol. In press
88. Rothstein JD, Bristol LA, Hosler B, Brown RH Jr, Kuncl RW. 1994. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc. Natl. Acad. Sci. USA 91:4155-59
89. Sanchez-Ramos J, Overvik E, Ames BN. 1994. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3:197-204
90. Sawa A, Khan AA, Hester LD, Snyder SH. 1997. Glyderaldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and non-neuronal cell death. Proc. Natl. Acad. Sci. USA 94:11669-74
91. Schapira AHV, Cooper JM, Dexter D, et al. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:823-27
92. Schlingensiepen KH, Wollnik F, Kunst M, Schlingensiepen R, Herdegen T, Brysch W. 1994. The role of Jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death, and plastic adaptations in vivo. Cell Mol. Neurobiol. 14:487-505
93. Schulz JB, Henshaw DR, Matthews RT, Beal MF. 1995a. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP toxicity. Exp. Neurol. 132:279-83
94. Schulz JB, Matthews RT, Muqit MMK, Browne SE, Beal MF. 1995b. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64:936-39
95. Scotcher KP, Irwin I, DeLanney LE, et al. 1990. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenyl-pyridinium ion on ATP levels of mouse synaptosomes. J. Neurochem. 54:1295-301
96. Sengstock GJ, Olanow CW, Dunn AJ, Arendash GW. 1993. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J. Neurosci. Res. 35:67-82
97. Sengstock G, Olanow CW, Dunn AJ, Barone S, Arendash G. 1994. Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra. Exp. Neurol. 130:82-94
98. Sian J, Dexter DT, Lees AJ, et al. 1994a. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36:348-55
99. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. 1994b. Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 36:356-61
100. Singer TP, Castagnoli N Jr, Ramsay RR, Trevor AJ. 1987. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem. 49:1-8
101. Sofic E, Lange KW, Jellinger K, Riederer P. 1992. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142:128-30
102. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. α-Synuclein in Lewy bodies. Nature 388:839-40
103. Steiner JP, Hamilton GS, Ross DT, Valentine HL, Guo H, et al. 1997. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc. Natl. Acad. Sci. USA 94:2019-24
104. Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, et al. 1996a. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J. Exp. Med. 184:1331-41
105. Susin SA, Zamzami N, Kroemer G. 1996b. The cell biology of apoptosis: evidence for the implication of mitochondria. Apoptosis 1:231-42
106. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, et al. 1996. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40:663-71
107. Tanner CM, Langston JW. 1990. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 40:17-30
108. Tanner CM, Ottman R, Ellenberg JH, et al. 1997. Parkinson's disease (PD) concordance in elderly mate monozygotic (MZ) and dizygotic (DZ) twins. Neurology 48:333
109. Tatton NA, Kish SJ. 1997. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77:1037-48
110. Tatton NA, Maclean-Fraser A, Tatton WG, Perl DF, Olanow CW. 1998. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann. Neurol. In press
111. Tatton WG, Chalmers-Redman RME. 1996. Modulation of gene expression rather than monoamine oxidase inhibition: (-) deprenyl-related compounds in controlling neuro-degeneration. Neurology 47:171-83
112. Tatton WG, Chalmers-Redmond RME, Ju WYH, Wadia J, Tatton NA. 1997. Apoptosis in neurodegenerative disorders: potentials for therapy by modifying gene transcription. J. Neural Transm. 49:245-67
113. Tatton WG, Ju WY, Holland DP, Tai C, Kwan M. 1994. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63:1572-75
114. Tatton WG, Ju WJH, Wadia J, Tatton NA. 1996. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. In Neuroprotection and Neurodegeneration, ed. CW Olanow, M Youdim, P Jenner, pp. 209-29. New York: Academic
115. Tatton WG, Olanow CW. 1998. Apoptosis in neurodegenerative disease: the role of mitochrondria. Biochim. Biophys. Acta. In press
116. Temlett JA, Landsberg JP, Watt F, Grime GW. 1994. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J. Neurochem. 62:134-46
117. Toffa S, Kunikowska GM, Zeng B-Y, Jenner P, Marsden CD. 1997. Chronic glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J. Neural Transm. 104:67-75
118. Tomac A, Lindqvist E, Lin LFH, Ogren SO, Young D, et al. 1995. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-39
119. Troy CM, Shelanski ML. 1994. Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. Proc. Natl. Acad. Sci. USA 91:6384-87
120. + neurotoxicity by NMDA antagonists. Nature 349:414-18
121. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, et al. 1993. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90:11282-86
122. Wadia JS, Chalmers-Redman RME, Ju WJH, Carlile GW, Phillips JL, Tatton WG. 1998. Mitochondrial membrane potential and nuclear changes in apoptosis caused by trophic withdrawal: time course and modification by (-) deprenyl. J. Neurosci. 18:932-47
123. Walkinshaw G, Waters CM. 1995. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J. Clin. Invest. 95:2458-64
124. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT. 1996. NACP, a protein implicated in Alzheimer's disease and learning, is naturally unfolded. Biochemistry 35:13709-15
125. Wood N. 1998. Genetic risk factors in Parkinson's disease. Ann. Neurol. In press
126. + toxicity in nigral dopaminergic neurones. NeuroReport 7:921-23
127. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. 1996. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc. Natl. Acad. Sci. USA 93:2696-713
128. Zoratti M, Szabo I. 1995. The mitochondrial permeability transition. Biochim. Biophys. Acta 1241:139-76